MethodSense Releases LuminLogic Version 7.0 in Support of Medical Device Companies' Compliance Efforts
LuminLogic 7.0 enables Medical Device Companies to expand their regulatory compliance efforts in a virtual compliant environment.
MORRISVILLE, N.C., May 12, 2020 (Newswire.com) - MethodSense, Inc., a medical device consulting firm, announces its release of LuminLogic 7.0, a 21 CFR Part 11 compliant SaaS solution that supports document, regulatory, quality and risk-management systems for the management of medical device and other life science companies' compliance efforts.
“The release of LuminLogic 6.0 earlier this year positioned our software as an enterprise scalable solution,” says Rita King, MethodSense CEO. “With the release of LuminLogic 7.0, we have launched a new wave of functionality in support of our clients’ compliance efforts, including Complaint Management, Corrective Action/Preventive Action (CAPA) management and Training management.
“What’s so exciting about LuminLogic 7.0 is the extension of the product’s highly intuitive interface and modular flexibility, with significant functional benefits to our clients.”
The new functionality enables the creation and assignment of a CAPA and Customer Complaint or Training documents for review and approval, as well as includes user notifications for high-impact user engagement, associated E-Signatures to document task completion and compliance and auditability to ensure compliance in the face of regulatory scrutiny.
“MethodSense’s clients, regardless of their size or the extent of their virtual operations, will benefit from these enhancements, particularly at a time when web-based collaboration is so critical during the pandemic and the anticipated expansion of remote offices anticipated in the future,” says Russ King, President of MethodSense.
For additional information, please contact Russ King at [email protected], (919) 607-4775 or via LuminLogic.
MethodSense, a medical device and combination product consulting firm, works with manufacturers, inventors and investors around the world to bring products to market and achieve business success in the U.S., E.U., Canada and other markets. Unmatched regulatory expertise and our purpose-built LuminLogic software platform uniquely position MethodSense to develop effective strategies for quality compliance and regulatory submissions, from initial filing to product launch and on-going quality and regulatory support. MethodSense has the answers. www.methodsense.com
###
Contact:
Russ King, President
O: 919.313.3962
C: 919.607.4775
email: [email protected]
www.methodsense.com
Source: MethodSense
Share:
Tags: Coronavirus, COVID-19, EUA Resource, FDA Emergency Use Authorization Guidance, FDA Review, Medical Device Approval
